Caroline Seymour

Stephen Liu, MD, provided an enhanced understanding of oncogenic drivers such as EGFR and ALK in patients with NSCLC, sequencing strategies, and the potential application of immunotherapy in later lines of therapy.

Ryan D. Gentzler, MD, highlights how chemotherapy remains a critical component of the metastatic non–small cell lung cancer treatment paradigm.

Lee Schwartzberg, MD, discusses a retrospective analysis of patients with nonmyeloid cancer who received a filgrastim biosimilar versus the filgrastim biologic and explains how biosimilars have the potential to transform the field of oncology beyond the scope of supportive care.

Leonid Shunyakov, MD, discusses the impact genomics has on personalized therapy and the roster of available therapies that continues to grow as a result of identifiable genomic drivers.

Jose M. Pacheco, MD, discusses the preferred therapeutic strategies for treating patients with NSCLC whose tumors harbor genetic alterations in EGFR, ALK, and ROS1.

James Larner, MD, discusses the process by which radiation interacts with the immune system and how physicians are working to improve treatment responses for patients with non–small cell lung cancer.

Jodie Barr, DO, discusses the evolution of treatment of patients with neuroendocrine tumors and the need for biomarkers.

Alexander R. Menter, MD, discusses treatment advances in early-stage non–small cell lung cancer (NSCLC).

Debu Tripathy, MD, discusses the evolution of treatment of patients with metastatic HR-positive breast cancer.

Robert M. Jotte, MD, PhD, addresses the underutilization of lung cancer screening in the United States and the importance of multidisciplinary management in improving patient outcomes.

Wendy A. Woodward, MD, PhD, highlights encouraging advances and ongoing developments with radiotherapy in breast cancer.

Dara L. Aisner, MD, PhD, discusses the rapidly progressing field of molecular profiling, the importance of understanding assay results, and how they translate to patient care in lung cancer.

Noa Biran, MD, discusses patient-reported outcomes following autologous stem cell transplant in patients with myeloma.

Naamit K. Gerber, MD, discusses recent advances in radiation therapy in the field of breast cancer.

Susanna Ulahannan, MD, highlights trials from the 2018 ASCO Annual Meeting across gastrointestinal malignancies and future therapeutic approaches across the landscape.

Robert L. Talley, MD, elaborates on the clinical trial findings that are shifting standards of care in chronic leukemias.

Sylvia Adams, MD, discusses the path forward for immunotherapy in triple-negative breast cancer.

Joseph Stilwill, MD, addresses recent advances in melanoma and the focus of research moving forward.

Mehmood Hashmi, MD, discusses the newly defined landscape of nonmetastatic castration-resistant prostate cancer, the potential with immunotherapy, and emerging imaging modalities.

Jessica Bauman, MD, addresses current and emerging therapeutic options for patients with BRAF, ROS1, and RET abnormalities in non–small cell lung cancer.

John A. Kosteva, MD, discusses the adoption of immunotherapy into the treatment paradigm for patients with non–small cell lung cancer.

Peter J. Van Veldhuizen, MD, discusses available and emerging therapies for patients with kidney cancer.

Yelena Novik, MD, shares her thoughts on the use of biosimilars in oncology and their potential impact on practice.

Charu Aggarwal, MD, discusses the latest developments in EGFR-mutant lung cancer.

Yelena Novik, MD, discusses the application of CDK4/6 inhibition and methods to overcome resistance in ER-positive breast cancer.

Liza C. Villaruz, MD, addresses the immunotherapy clinical trials that have informed the treatment of patients with NSCLC and the current state of biomarkers in the field.

Deborah Krakow, MD, discusses the value of a patient’s family history and its implications on genetic counseling.

Christopher J. Pietras, MD, discusses the elements of palliative care for patients with ovarian cancer.

Sanaz Memarzadeh, MD, PhD, details the early developments of antibody-directed therapies and restoring p53 function in the treatment of patients with ovarian cancer.

Gottfried E. Konecny, MD, discusses developments in the understanding of response to PARP inhibition in ovarian cancer.